NCT05614739 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05614739
Title	FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1)
Acronym	FORAGER-1
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Eli Lilly and Company
Indications	bladder urothelial carcinoma transitional cell carcinoma Advanced Solid Tumor invasive bladder transitional cell carcinoma
Therapies	Enfortumab vedotin-ejfv + LOXO-435 + Pembrolizumab LOXO-435 Digoxin + LOXO-435 + Midazolam + Rosuvastatin LOXO-435 + Trastuzumab deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS

Additional content available in CKB BOOST